Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient’s CD8+ “killer” T-cells against cancer. Heat’s T-cell Activation Platform (TCAP) produces therapies designed to turn “cold” tumors “hot” and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness.Product candidates are produced from allogeneic cell lines composed of tumor proteins common among all cancers. The immunotherapies combine a T-cell activator and a T-cell co-stimulator into a single drug, eliminating the need for multiple, independent biologic treatments.
|Bank Name||Heat Biologics, Inc.|
|Chairman||Mr. Jeffrey Alan Wolf|
|CEO||Mr. Jeffrey Alan Wolf|